Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients ≥65 years old,Muscle & Nerve

当前位置： X-MOL 学术 › Muscle Nerve › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients ≥65 years old
Muscle & Nerve ( IF 2.8 ) Pub Date : 2021-08-11 , DOI: 10.1002/mus.27393
Christopher T Doughty _{1,

2} , Joome Suh _{1,

2,

3} , William S David _{2,

3} , Anthony A Amato _{1,

2} , Amanda C Guidon _{2,

3}

Affiliation

Optimal management of myasthenia gravis (MG) in individuals ≥65 y old is unknown and patient factors may limit therapeutic choices. Safety and efficacy of rituximab in older patients with MG has not been well-studied.

中文翻译：